Posted by Michael Wonder on 30 Nov 2021
TRACON Pharmaceuticals reports regulatory approval of envafolimab in China
29 November 2021 - First approval of a subcutaneously administered checkpoint inhibitor.
TRACON Pharmaceuticals today reported that its partners Alphamab Oncology and 3D Medicines announced that envafolimab (KN035), the world's first single-domain PD-L1 antibody formulated for subcutaneous injection received marketing authorisation from the Chinese National Medical Products Administration.
